by Rich Winkel, ThoughtCrimeRadio:
LONDON — The first patients have been enrolled in human trials for a coronavirus vaccine at the historic University of Oxford after the U.K.’s Health Secretary said the country would be “throwing everything” behind the project.
The clinical trial will test the effects of possible COVID-19 treatments and the start the process of vaccine evaluation in the university’s first human studies….
Earlier this week, the Health Secretary Matt Hancock announced a total of £52.5 million (about $65 million) worth of funding for the project, and another vaccine trial at London’s Imperial University due to begin in June.
“Both of these promising projects are making rapid progress and I’ve told the scientists leading them we will do everything in our power to support,” Hancock said at a Downing Street briefing on Tuesday. “After all, the upside of being the first country in the world to develop a successful vaccine is so huge that I am throwing everything at it.”
Although the university has urged caution when it comes to mapping out a firm timeline for when the vaccine — called ChAdOx1 nCoV-19 — would be in development, a best-case scenario could see for the vaccine’s efficacy determined by fall 2020. Under normal circumstances, even at high speed, it can take between 12 and 18 months to develop a vaccine….
There are more than 80 vaccines currently in development globally, and several therapeutic drugs to treat the novel coronavirus are also in clinical trials, the WHO told ABC News….
PARTICIPANT INFORMATION SHEET:
The vaccine we are testing in this research study is called ChAdOx1 nCoV-19. ChAdOx1 nCoV-19 is made from a virus (ChAdOx1), which is a weakened version of a common cold virus (adenovirus) from chimpanzees that has been genetically changed so that it is impossible for it to grow in humans. To this virus we have added genes that make proteins from the COVID-19 virus (SARS-CoV-2) called Spike glycoprotein (S), which play an essential role in the infection pathway of the SARS-CoV-2 virus. …
What is the control (comparison) vaccine?
In this study we will be using a licensed vaccine against group A, C, W and Y meningococcus (MenACWY) as an ‘active control’ vaccine, to help us understand participants’ response to ChAdOx1 nCoV-19….
In other words, there is no placebo, no saline solution etc. Cuz ideally the control needs to be at least as toxic as the trial vaccine if they hope to gain approval. Makes sense.